Tonix enrolls first patient in Phase 2 MDD study of TNX-102 SL (TONMYA)

Tonix Pharmaceuticals Holding Corp.

First patient enrolled in HORIZON, a potentially pivotal Phase 2 study of TNX-102 SL 5.6 mg as first-line monotherapy for major depressive disorder.
Primary endpoint: change from baseline in MADRS total score at Week 6; about 360 patients at ~30 US sites.
TNX-102 SL (TONMYA) was FDA approved for fibromyalgia in August 2025; MDD indication is investigational.
CEO notes TNX-102 SL targets poor sleep quality; prior signals in PTSD and fibromyalgia studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.